Ligand ID: CBL Drugbank ID: DB00291(Chlorambucil) Indication:For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 1ssk | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 5 / 9 | TYR A 65PHE A 44VAL A 111GLY A 63GLY A 49 | 1.55A | 20.56 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 5 / 9 | PHE D 314PRO D 280GLY D 285ILE B 313GLY D 315 | 1.74A | 26.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAINREPLICASEPOLYPROTEIN 1AB,LIGHT CHAIN (SARSr-CoV) | 5 / 9 | PRO F 121VAL F 120GLY F 118ARG F 116GLY B 69 | 1.63A | 21.55 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2ajf | SPIKE PROTEIN (SARSr-CoV) | 5 / 9 | PHE F 483GLY F 488ARG F 426TYR F 494GLY F 391 | 1.70A | 22.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2cjr | NUCLEOCAPSID PROTEIN (SARS-COVTW1) | 5 / 9 | PHE H 275VAL H 271GLY H 296ILE H 305GLY H 288 | 1.78A | 19.80 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2dd8 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE S 483GLY S 488ARG S 426TYR S 494GLY S 391 | 1.67A | 21.79 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2ghw | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE A 483GLY A 488ARG A 426TYR A 494GLY A 391 | 1.65A | 21.46 | None CL A 88 (-3.3A)NoneNoneNone | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 2ofz | NUCLEOCAPSID PROTEIN (SARS-COVTor2) | 5 / 9 | PRO A 74VAL A 73ILE A -3TYR A 124GLY A 86 | 1.56A | 21.03 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 5 / 9 | PHE S 483GLY S 488ARG S 426TYR S 494GLY S 391 | 1.72A | 22.27 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3d0g | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 483GLY E 488ARG E 426TYR E 494GLY E 391 | 1.62A | 22.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3d0h | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 483GLY E 488ARG E 426TYR E 494GLY E 391 | 1.64A | 22.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3d0i | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 483GLY E 488ARG E 426TYR E 494GLY E 391 | 1.59A | 22.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3sci | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE F 483GLY F 488ARG F 426TYR F 494GLY F 391 | 1.63A | 22.55 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3scj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 483GLY E 488ARG E 426TYR E 494GLY E 391 | 1.64A | 22.27 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3sck | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 483GLY E 488ARG E 426TYR E 494GLY E 391 | 1.59A | 22.27 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 3scl | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE F 483GLY F 488ARG F 426TYR F 494GLY F 391 | 1.59A | 22.75 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 9 | PHE B 483GLY B 488ARG B 426TYR B 494GLY B 391 | 1.75A | 10.15 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 5x5c | S PROTEIN (MERS-CoV) | 5 / 9 | PHE C 786PRO C1143GLY C1140ILE C 976GLY C 984 | 1.66A | 9.96 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ack | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE B 483GLY B 488ARG B 426TYR B 494GLY B 391 | 1.67A | 10.15 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 9 | PHE C 483GLY C 488ARG C 426TYR C 494GLY C 391 | 1.57A | 9.83 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6m3m | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 9 | PRO B 74VAL B 73ARG B 69TYR B 124GLY B 86 | 1.51A | 20.00 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6vw1 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE E 497GLY E 502ARG E 439TYR E 508GLY E 404 | 1.62A | 23.43 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6vyo | NUCLEOPROTEIN (SARS-CoV-2) | 5 / 9 | PRO C 73VAL C 72ARG C 68TYR C 123GLY C 85 | 1.51A | 21.43 | None | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6w02 | NSP3 (SARS-CoV-2) | 5 / 9 | PHE B 132PRO B 98VAL B 100GLY B 103GLY B 133 | 1.73A | 21.97 | APR B 201 (-3.5A)NoneNoneNoneNone | ||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 9 | PHE B 132PRO B 98VAL B 100GLY B 103GLY B 133 | 1.78A | MES B 201 ( 3.4A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 9 | PHE A 132PRO A 98VAL A 100GLY A 103GLY A 133 | 1.73A | MES A 201 (-2.5A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 9 | PRO A 73VAL A 72ARG A 68TYR A 123GLY A 85 | 1.54A | None | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 9 | PRO D 73VAL D 72ARG D 68TYR D 123GLY D 85 | 1.56A | None | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 9 | PRO B 73VAL B 72ARG B 68TYR B 123GLY B 85 | 1.58A | None | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | PHE C 132PRO C 98VAL C 100GLY C 103GLY C 133 | 1.74A | APR C 201 (-3.5A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | PHE A 132PRO A 98VAL A 100GLY A 103GLY A 133 | 1.78A | APR A 201 (-3.1A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | PHE B 132PRO B 98VAL B 100GLY B 103GLY B 133 | 1.71A | APR B 201 (-3.6A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | PHE D 132PRO D 98VAL D 100GLY D 103GLY D 133 | 1.76A | APR D 201 (-3.5A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6yi3 | NUCLEOPROTEIN (SARS-CoV-2) | 5 / 9 | PRO A 33VAL A 32ARG A 28TYR A 83GLY A 45 | 1.34A | None | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE D 132PRO D 98VAL D 100GLY D 103GLY D 133 | 1.78A | EDO D 205 ( 3.6A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE E 132PRO E 98VAL E 100GLY E 103GLY E 133 | 1.78A | EPE E 202 (-3.2A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE A 132PRO A 98VAL A 100GLY A 103GLY A 133 | 1.79A | EDO A 202 (-3.9A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE B 132PRO B 98VAL B 100GLY B 103GLY B 133 | 1.79A | APR B 201 (-3.5A)NoneNoneNoneNone | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE B 132PRO B 98VAL B 100GLY B 103GLY B 133 | 1.79A | None | |||
![]() | 3CSJ_B_CBLB211_0 (GLUTATHIONES-TRANSFERASE P) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE C 132PRO C 98VAL C 100GLY C 103GLY C 133 | 1.78A | MES C 201 (-3.6A)NoneNoneNoneNone |